Schrodinger, Inc. SDGR
We take great care to ensure that the data presented and summarized in this overview for Schrodinger, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SDGR
View all-
Black Rock Inc. New York, NY8.52MShares$218 Million0.0% of portfolio
-
Bill Gates Bill & Melinda Gates Foundation Trust | Kirkland, Wa6.98MShares$179 Million0.32% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$169 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY5MShares$128 Million1.59% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.46MShares$88.7 Million0.05% of portfolio
-
Nikko Asset Management Americas, Inc.2.46MShares$63.2 Million0.53% of portfolio
-
State Street Corp Boston, MA2.32MShares$59.4 Million0.0% of portfolio
-
Massachusetts Financial Services CO Boston, MA2.28MShares$58.4 Million0.01% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.21MShares$56.6 Million0.37% of portfolio
-
Credit Suisse Ag Zurich, V81.99MShares$51 Million0.05% of portfolio
Latest Institutional Activity in SDGR
Top Purchases
Top Sells
About SDGR
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Insider Transactions at SDGR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 14
2025
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
16,723
-21.46%
|
$418,075
$25.07 P/Share
|
|
Apr 14
2025
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
16,723
+20.47%
|
$50,169
$3.07 P/Share
|
|
Mar 07
2025
|
Bridget A Van Kralingen Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Mar 06
2025
|
Jenny Herman SVP & Controller |
SELL
Open market or private sale
|
Direct |
666
-2.38%
|
$13,986
$21.11 P/Share
|
|
Mar 03
2025
|
Geoffrey Craig Porges EVP & CFO |
SELL
Open market or private sale
|
Direct |
5,491
-16.62%
|
$115,311
$21.76 P/Share
|
|
Mar 03
2025
|
Geoffrey Craig Porges EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
27,350
+35.87%
|
-
|
|
Mar 03
2025
|
Robert Lorne Abel Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+37.75%
|
-
|
|
Mar 03
2025
|
Yvonne Tran EVP, CLO & CPO |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+34.59%
|
-
|
|
Mar 03
2025
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+18.92%
|
-
|
|
Mar 03
2025
|
Jenny Herman SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
9,800
+25.92%
|
-
|
|
Mar 03
2025
|
Margaret Dugan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.49%
|
-
|
|
Mar 03
2025
|
Ramy Farid President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+14.45%
|
-
|
|
Mar 03
2025
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Grant, award, or other acquisition
|
Direct |
15,625
+50.0%
|
-
|
|
Feb 18
2025
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
3,902
-25.95%
|
$109,256
$28.0 P/Share
|
|
Feb 18
2025
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,902
+20.6%
|
$15,608
$4.34 P/Share
|
|
Feb 11
2025
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
828
-6.92%
|
$19,872
$24.43 P/Share
|
|
Feb 11
2025
|
Jenny Herman SVP & Controller |
SELL
Open market or private sale
|
Direct |
859
-4.5%
|
$20,616
$24.43 P/Share
|
|
Feb 11
2025
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
985
-2.34%
|
$23,640
$24.43 P/Share
|
|
Feb 10
2025
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
1,225
-13.12%
|
$30,625
$25.99 P/Share
|
|
Oct 15
2024
|
Margaret Dugan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,531
-10.21%
|
$26,027
$17.78 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 190K shares |
|---|---|
| Exercise of conversion of derivative security | 20.6K shares |
| Open market or private sale | 32.2K shares |
|---|